Business Wire

C3.ai Digital Transformation Institute Announces Call for Papers to Advance AI for Energy and Climate Security

2.2.2021 14:00:00 EET | Business Wire | Press release

Share

The C3.ai Digital Transformation Institute invites scholars, software developers, and researchers to address the challenge of re-envisioning energy systems with artificial intelligence (AI) and digital transformation to lead the way to a lower-carbon, higher-efficiency economy that will enhance both energy and climate security.

“Mitigating the impact of global energy generation will require a massive transformation of the world’s energy infrastructure,” said Thomas M. Siebel, chairman and CEO of C3 AI, a leading enterprise AI software provider for accelerating digital transformation. “This call for proposals covers topics that aim to provide safer, cleaner, lower cost, and more reliable energy through the application of AI.”

Immediate Call for Proposals : AI and Digital Transformation for Energy and Climate Security.

Topics for research awards may include, but are not limited to, the following:

  1. Sustainability: Applying AI, machine learning, and advanced analytic techniques to support sustainability initiatives for energy consumption and greenhouse gas emissions

  2. AI for Carbon Sequestration: Applying AI/ML techniques to increase the scale and reduce the cost of carbon sequestration

  3. AI for Leaks and Emissions Detection: Applying advanced AI/ML techniques for large-scale emissions detection, facility-level data reconciliation and gap analysis for emissions sensors, prediction of emissions risk, and analysis and optimization of flaring intensity across upstream and downstream operations

  4. Safe Hydrocarbon Production and Transportation Infrastructure: Applying analytic and AI/ML modeling techniques to increase the safety and reduce emissions from oil and gas extraction, petrochemical production, and hydrocarbon transportation

  5. AI for Advanced Energy and Carbon Markets: Enabling dynamic, automated, and real-time pricing of energy generation sources

  6. Cybersecurity of Power and Energy Infrastructure: Leveraging AI/ML techniques to improve the cybersecurity of our critical power and energy assets, as well as smart connected factories and homes

  7. Smart Grid Analytics: Applying AI and other analytic approaches to improve the efficiency and effectiveness of grid transmission and distribution operations

  8. Distributed Energy Resource Management: Applying AI to increase the penetration and use of distributed renewables

  9. AI for Energy-Efficient Buildings and Factories: Leveraging AI techniques for advanced building and factory control to improve energy efficiency

  10. AI for Improved Natural Catastrophe Risk Assessment: Applying AI to improve modeling of natural catastrophe risks from future weather-related events (e.g., tropical storms, wildfires, and floods)

  11. Resilient Energy Systems: Addressing how the use of AI/ML techniques and markets for energy and carbon introduce new vulnerabilities

  12. AI for Improved Climate Change Modeling: Use of AI/ML to address climate change modeling and adaptation

“The energy industry is at a critical inflection point to accelerate delivery of cleaner, safer energy while meeting growing demand,” said Lorenzo Simonelli, chairman and CEO of Baker Hughes, an energy technology company serving energy and industrial customers worldwide. “We are excited about our partnership with the C3.ai Digital Transformation Institute and the impact these funded research projects will have in advancing AI at scale for the energy transition.”

This second call for proposals is open now, with a submission deadline of March 29, 2021. Researchers are invited to learn more about C3.ai DTI and how to submit their proposals for consideration at C3DTI.ai. Selected proposals will be announced in mid-May, with start dates of June 1, 2021.

Up to $5 million in cash awards will be funded from this second call, ranging from $100,000 to $250,000 each. In addition to cash awards, C3.ai DTI recipients will be provided with significant cloud computing, supercomputing, data access, and AI software resources and technical support provided by Microsoft and C3 AI. This will include unlimited use of the C3 AI® Suite, access to the Microsoft Azure cloud platform, and access to the Blue Waters supercomputer at the National Center for Supercomputing Applications (NCSA) at the University of Illinois at Urbana-Champaign.

Establishing the New Science of Digital Transformation

C3.ai DTI focuses its research on AI, machine learning, IoT, big data analytics, human factors, organizational behavior, ethics, and public policy. The Institute supports the development of ML algorithms, data security, and cybersecurity techniques. C3.ai DTI research analyzes new business operation models, develops methods of implementing organizational change management and protecting privacy, and amplifies the dialogue around the ethics and public policy of AI.

About C3.ai Digital Transformation Institute

C3.ai Digital Transformation Institute represents an innovative vision to take AI, ML, IoT, and big data research in a consortium model to a level that cannot be achieved by any one institution alone. Jointly managed and hosted by the University of California, Berkeley and the University of Illinois at Urbana-Champaign, C3.ai DTI attracts the world’s leading scientists to join in a coordinated and innovative effort to advance the digital transformation of business, government, and society, and establish the new science of digital transformation. To support the Institute, C3 AI will provide $57,250,000 in cash contributions over the first five years of operation. C3 AI and Microsoft will contribute an additional $310 million in-kind, including use of the C3 AI Suite and Microsoft Azure computing, storage, and technical resources to support C3.ai DTI research.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

C3.ai DTI Contact:
Kap Stann
Communications Manager, C3.ai DTI @ Berkeley
Tel. +1 510-295-9685
Kstann@berkeley.edu

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

LabPMM® Launches Global KMT2A MRD Testing Service to Support Menin Inhibitor Development and Acute Leukemia Care4.8.2026 10:10:00 EEST | Press release

LabPMM®, an Invivoscribe® subsidiary, today announced the global availability of its new KMT2A measurable residual disease (MRD) testing service. The highly sensitive digital PCR service is available to healthcare providers, clinical researchers, and biopharmaceutical partners through LabPMM’s global laboratory network, with CAP/CLIA-accredited testing available in the U.S. The service addresses a growing need for accurate molecular monitoring in acute leukemias.1,2,3 KMT2A rearrangements (KMT2Ar) are oncogenic drivers in acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL).4 These rearrangements are present in about 80% of infant cases and 5-15% of childhood and adult leukemia cases.5 KMT2Ar leukemias are associated with chemotherapy resistance, high relapse rates, and poor clinical outcomes.5 The emergence of menin inhibitors is transforming the therapeutic landscape for patients with AML and ALL, particularly those with KMT2A-rearranged and NPM1-mutated disease.6 The

Mosaic Therapeutics appoints Dr Allison Jeynes as Chair of the Board4.8.2026 10:00:00 EEST | Press release

Mosaic Therapeutics, Ltd, (‘Mosaic’, or ‘the Company’) an oncology therapeutics company developing novel, targeted drug combinations across a range of haematological and solid cancers, today announced the appointment of Dr Allison Jeynes as Chair of the Board to support its next phase of growth and advancement towards clinical development. Allison succeeds Dr Edward Hodgkin, who remains a Non-Executive Director of the Board. Allison is a UK-trained oncologist and highly-experienced life sciences leader, and brings over three decades of drug development and executive experience to Mosaic Therapeutics. As CEO of Avillion, a clinical development company, for the last 13 years, she has led global teams to achieve a 100% success rate from Phase 3 development through to FDA approval for multiple programs spanning oncology, immunology and respiratory medicine. In addition, she raised funds of around $400M as founder and CEO. Across her career she has contributed to 20 drug approvals, engaging

TOHKnet and Adtran conduct Japan’s first 50G PON trial on a live network4.8.2026 10:00:00 EEST | Press release

Adtran today announced that TOHKnet has completed Japan’s first live network trial demonstrating the coexistence of 50G PON, XGS-PON and EPON on a single fiber. Conducted in Sendai using Adtran’s SDX 6400 Series OLT, the demo showed how the platform enables three generations of PON technology to operate together in a live service environment. The results highlight a realistic path for operators to introduce 50G PON capacity while maintaining continuity for existing services, maximizing the value of deployed fiber assets and reducing the complexity and disruption typically associated with network upgrades. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260803353435/en/ Adtran’s SDX 6400 Series is helping TOHKnet demonstrate how Japan’s operators can migrate to 50G PON without disrupting existing PON services. “As demand for digital services continues to grow, this trial is a key milestone for the future of fiber access in Jap

“HATSUNE MIKU LIGHTS TOKYO” Debuts on July 254.8.2026 10:00:00 EEST | Press release

The Tokyo Metropolitan Government has been presenting year-round projection mapping displays on the Tokyo Metropolitan Government Building, using light and sound to showcase a wide range of artistic expressions as part of its efforts to create new nighttime tourism attractions in Tokyo. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260802298570/en/ © Crypton Future Media, INC. On Saturday, July 25, "HATSUNE MIKU LIGHTS TOKYO", featuring the globally beloved virtual singer Hatsune Miku, held its first screening. The work brings the world of the popular song “M@GICAL☆CURE! LOVE ♥ SHOT!” to life across the entire façade of the Tokyo Metropolitan Government Building. Since its launch in February 2024, “TOKYO Night & Light” has welcomed visitors from Japan and around the world, with total attendance surpassing 1.55 million. As one of Tokyo’s emerging landmark attractions, the project continues to captivate audiences through its

Evexta Bio Announces Clinical Trial Collaboration and Supply Agreement with Roche to Evaluate Rupitasertib in Combination with a Selective Estrogen Receptor Degrader in Advanced / Metastatic Breast Cancer4.8.2026 10:00:00 EEST | Press release

Evexta Bio S.A., a precision oncology company, founded by Truffle Capital (founder of Abivax and Carvolix), and focused on the discovery and development of targeted therapies, today announced a clinical collaboration and supply agreement with plans to initiate a Phase 1b study combining its lead investigational compound, rupitasertib, with Roche’s investigational compound giredestrant, a selective estrogen receptor degrader (SERD), for the treatment of ER+, HER2-, ESR1-mutated advanced / metastatic breast cancer. Rupitasertib, is a first-in-class oral dual-node PI3K/AKT/mTOR (PAM) pathway inhibitor, which selectively inhibits S6K and AKT1/3. Rupitasertib was purposefully and rationally designed to target S6K for potent PAM inhibition and AKT1/3 to block the AKT compensatory feedback loop, while sparing AKT2 to avoid hyperglycemia, which we believe will lead to a superior efficacy and safety profile compared to other PAM pathway inhibitors. Under the terms of the agreement, Roche will s

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye